The cancer diagnostics firm said the new funding will go toward bringing new cancer diagnostics to market and to pay off debt.
Rosetta entered into a definitive agreement with an institutional healthcare investor for a $2 million private placement.
The company said that it will use the funds to accelerate the commercialization of its proprietary Cell Bound Complement Activation Products technology.
Notable Labs, a drug testing service for oncologists identifying treatment options for blood-cancer patients, has raised $17 million since 2014.
The firm plans to use the funding to expand commercial sales efforts, advance CDx partnerships, build its regulatory infrastructure, and explore new R&D avenues.
The company said that the funds will allow it to take its ReadyPlex rapid blood group genotyping assays into clinical trials and commercialization.
The funding was led by T. Rowe Price and will be used by Quanterix to develop new instruments, expand the firm's assay menu, and other things.
The company is expecting $14.3 million in Q2 revenues, a 157 percent increase over the same quarter last year.
The financing will go toward efforts by the German firm to bring its point-of-care screening system for drug-resistant bacteria to hospitals.
The Series A financing will be used to commercialize its lung cancer diagnostic test and develop tests for other cancers.